Reducing Failure-to-Initiate ART: Streamlined ART Start Strategy (START)
减少 ART 启动失败的情况:简化的 ART 启动策略 (START)
基本信息
- 批准号:8613427
- 负责人:
- 金额:$ 88.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-01 至 2015-06-30
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAdherenceAdoptionAffectAfricaAnatomyAttitudeBehaviorBeliefCD4 Lymphocyte CountCD4 Positive T LymphocytesCaringCessation of lifeCharacteristicsClinicCommunitiesCounselingDataEducationEffectivenessEligibility DeterminationEnabling FactorsEnrollmentEvidence based practiceFailureFeedbackGoalsHIVHealthHealth PlanningImpact evaluationIndividualInfectionInformation DisseminationInterventionJointsKnowledgeMeasuresMethodsMetricModelingMorbidity - disease rateNewly DiagnosedOpportunistic InfectionsOutcomeOutcome AssessmentPatientsPredisposing FactorPregnant WomenPreparationProcessProfessional counselorProviderPublic HealthRNARandomizedReinforcing FactorReportingResourcesRuralSafetyServicesSpecimenStagingSubgroupSystemTestingTimeUgandaUse EffectivenessVertical Disease Transmissionantiretroviral therapybaseburden of illnesscell determinationcostcost effectivenessdisability-adjusted life yearsfollow-uphealth care deliveryimprovedinterestmedication compliancemeetingsmembermortalitynovel strategiespoint of careprogramspublic health prioritiespublic health relevanceroutine carestandard of caretherapy adherenceuptake
项目摘要
DESCRIPTION (provided by applicant): Over 30% of identified ART-eligible patients fail to initiate (FTI) ART resulting in increased rates of early mortality, MTCT and AIDS illnesses. Failures in ART initiation are predominantly based in the systems conditions in resource limited settings: 1) delays in obtaining CD4 cell counts for ART eligibility, 2) provider misconceptions of
the urgency of ART initiation among specific patient groups, and 3) multiple pre-ART adherence counseling sessions and support requirements. We have developed a multi-component Streamlined ART Start Strategy (START) based on an empirically validated model of change that deploys 1) portable point of care (POC) CD4 testing and adapted counseling to enable ART start, 2) dissemination of information through education that predisposes provider behavior and 3) feedback reporting on FTIs that reinforces uptake of ART. We now propose to test this intervention in a randomized, controlled stepped-wedge trial of 24 clinics in Uganda through our PEPFAR supported Mulago-Mbarara Joint AIDS Program (MMJAP). Aim 1: Evaluate the effect of START on ART initiation. Specifically, we will compare the overall time to and completeness of ART initiation among those randomized to immediate and delayed implementation of START. We will conduct subgroup analyses in patients with TB and a CD4 < 50/¿l, all WHO Stage 4 patients and - given Uganda's recent adoption full ART as a strategy for pMTCT - pregnant women with a CD4 < 350/¿l. In addition, we plan to measure and evaluate the specific sub-intervals (e.g. between patient enrollment, request for CD4 testing, procurement of the specimen, etc.) that comprise the "anatomy" of the ART initiation process so that specific efficiencies and bottlenecks in the intervention can be identified. Aim 2: Evaluate the effect of START on mortality and other outcomes using supplemental outcome ascertainment through tracking patients who are lost to follow up in the community. Understanding the causal effect of a new implementation strategy on "hard" endpoints such as survival in real-world settings is a key objective of impact evaluation. Under program settings in Africa, however, high loss to follow-up (i.e. unknown outcomes) leads to biased assessment of outcomes. Our group has developed an approach to manage loss to follow-up based on active ascertainment of outcomes through patient tracking in the community. We will adapt this method to evaluate HIV RNA suppression as well as mortality. Aim 3: Assess the cost and cost-effectiveness of START. Streamlined ART initiation may not only save lives but also increase efficiency, by decreasing resources per patient and increasing yield to ART. Using effectiveness obtained in Aims 1 and 2 and clinic and individual level costing data, we will estimate the cost and cost-effectiveness of START versus standard of care for ART initiation. Outcomes of interest will include cost per: confirmation of meeting ART criteria; ART initiation; virologic suppression; averted death; averted vertical infection; and averted Disability-Adjusted Life Year (DALY).
描述(由申请人提供):超过30%的确定的ART合格患者未能开始(FTI)ART,导致早期死亡率,母婴传播和艾滋病疾病的增加。ART启动失败主要基于资源有限环境中的系统条件:1)获得ART资格的CD 4细胞计数的延迟,2)提供者对ART的误解,
在特定患者群体中启动ART的紧迫性,以及3)多次ART前依从性咨询会议和支持要求。我们已经开发了一个多组件的简化ART启动策略(START),该策略基于经验验证的变化模型,该模型部署了1)便携式护理点(POC)CD 4检测和适应性咨询,以使ART启动,2)通过教育传播信息,使提供者的行为倾向,3)对FTI的反馈报告,加强ART的摄取。通过我们的PEPFAR支持的Mulago-Mbarara联合艾滋病计划(MMJAP),在乌干达的24个诊所进行了对照阶梯楔形试验。目的1:评估START对ART启动的影响。具体来说,我们将比较随机分配到立即和延迟实施START的患者中开始ART的总时间和完成情况。我们将对CD 4 < 50/L的结核病患者、所有世卫组织第4期患者以及CD 4 < 350/L的孕妇进行亚组分析,因为乌干达最近采用了全面抗逆转录病毒疗法作为预防母婴传播的战略。此外,我们计划测量和评价特定的子间隔(例如,患者入组、CD 4检测请求、标本采购等之间)。包括ART启动过程的“解剖学”,以便可以确定干预的具体效率和瓶颈。目标二:通过跟踪社区失访患者,使用补充结局确定评估START对死亡率和其他结局的影响。了解新的实施战略对“硬”终点(如现实环境中的生存率)的因果影响是影响评价的一个关键目标。然而,在非洲的项目设置下,高失访率(即未知结局)导致对结局的偏倚评估。我们的团队已经开发出一种方法来管理失访,该方法基于通过社区中的患者跟踪来积极确定结果。我们将采用这种方法来评估HIV RNA抑制以及死亡率。目标3:评估裁武条约的成本和成本效益。简化的ART启动不仅可以挽救生命,而且还可以提高效率,通过减少每例患者的资源和增加产量的ART。使用目标1和2中获得的有效性和诊所和个人水平的成本数据,我们将估计成本和成本效益的START与标准的护理ART启动。关注的结果将包括以下成本:确认符合ART标准; ART启动;病毒学抑制;避免死亡;避免垂直感染;避免残疾调整生命年(DALY)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Diane V Havlir其他文献
Dynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and Kenya: a randomised trial extension
乌干达和肯尼亚农村地区使用卡博特韦长效注射剂进行动态选择的艾滋病毒预防:一项随机试验扩展
- DOI:
10.1016/s2352-3018(24)00235-2 - 发表时间:
2024-11-01 - 期刊:
- 影响因子:13.000
- 作者:
Moses R Kamya;Laura B Balzer;James Ayieko;Jane Kabami;Elijah Kakande;Gabriel Chamie;Nicole Sutter;Helen Sunday;Janice Litunya;Joshua Schwab;John Schrom;Melanie Bacon;Catherine A Koss;Alex R Rinehart;Maya Petersen;Diane V Havlir;SEARCH Consortium - 通讯作者:
SEARCH Consortium
Diane V Havlir的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Diane V Havlir', 18)}}的其他基金
A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East Africa
解决东非艾滋病毒流行的持续驱动因素的多部门战略
- 批准号:
10267216 - 财政年份:2020
- 资助金额:
$ 88.75万 - 项目类别:
A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East Africa
解决东非艾滋病毒流行的持续驱动因素的多部门战略
- 批准号:
10085144 - 财政年份:2020
- 资助金额:
$ 88.75万 - 项目类别:
A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East Africa
解决东非艾滋病毒流行的持续驱动因素的多部门战略
- 批准号:
10438844 - 财政年份:2020
- 资助金额:
$ 88.75万 - 项目类别:
Strategic antiretroviral therapy and HIV testing for youth in rural Africa
为非洲农村青年提供战略性抗逆转录病毒治疗和艾滋病毒检测
- 批准号:
10216460 - 财政年份:2018
- 资助金额:
$ 88.75万 - 项目类别:
Strategic antiretroviral therapy and HIV testing for youth in rural Africa
为非洲农村青年提供战略性抗逆转录病毒治疗和艾滋病毒检测
- 批准号:
10252946 - 财政年份:2018
- 资助金额:
$ 88.75万 - 项目类别:
Strategic antiretroviral therapy and HIV testing for youth in rural Africa
为非洲农村青年提供战略性抗逆转录病毒治疗和艾滋病毒检测
- 批准号:
10469425 - 财政年份:2018
- 资助金额:
$ 88.75万 - 项目类别:
Simplified Isoniazid Preventive Therapy (SPIRIT) Strategy to Reduce TB Burden
减少结核病负担的简化异烟肼预防治疗 (SPIRIT) 策略
- 批准号:
10343685 - 财政年份:2016
- 资助金额:
$ 88.75万 - 项目类别:
Simplified Isoniazid Preventive Therapy (SPIRIT) Strategy to Reduce TB Burden
减少结核病负担的简化异烟肼预防治疗 (SPIRIT) 策略
- 批准号:
10064569 - 财政年份:2016
- 资助金额:
$ 88.75万 - 项目类别:
Reducing Failure-to-Initiate ART: Streamlined ART Start Strategy (START)
减少 ART 启动失败的情况:简化的 ART 启动策略 (START)
- 批准号:
8295938 - 财政年份:2012
- 资助金额:
$ 88.75万 - 项目类别:
Reducing Failure-to-Initiate ART: Streamlined ART Start Strategy (START)
减少 ART 启动失败的情况:简化的 ART 启动策略 (START)
- 批准号:
8705385 - 财政年份:2012
- 资助金额:
$ 88.75万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 88.75万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 88.75万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 88.75万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 88.75万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 88.75万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 88.75万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 88.75万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 88.75万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 88.75万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 88.75万 - 项目类别:
Fellowship Programs